1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Decipher Labs Ltd.

Decipher Labs Ltd.

BBSE:DECIPHER
5.08
INR
-0.31
(-5.75%)
-1.82EPS
67.90MMarket Cap
Decipher Labs Ltd.
BSE:DECIPHER
(Bombay Stock Exchange)

Recent

price

5.08

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
1.21
- -
0.63
0.06
0.12
0.28
0.47
1.27
10.07
23.75
55.01
64.68
45.12
35.52
22.39
13.91
13.4
Revenue per Share
0.01
- -
-0.18
-1
-4.6
-1.6
-0.23
0.23
0.51
1.09
1.39
11.27
-2.66
-1.66
-5.03
-3.05
-1.82
Basic EPS, GAAP
-2.48
- -
-0.12
- -
0.12
-0.31
-0.02
-0.12
0.28
-15.27
1.5
7.99
-2.32
4.75
-9.78
-2.66
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
5.36
10
9.83
8.85
4.25
2.65
2.42
2.65
3.16
12.44
13.55
23.93
22.98
21.64
22.63
20.46
- -
Book Value per Share
5.24
10
9.83
8.85
4.25
2.65
2.42
2.65
3.16
9.35
10.86
21.46
20.65
19.64
20.93
19
- -
Tangible Book Value per Share
3
8
8
8
8
8
8
8
8
10
10
10
10
10
10
10
10
Basic Weighted Avg Shares
4
- -
5
- -
1
2
4
10
81
240
556
653
456
359
226
141
135
Sales/Revenue/Turnover
1.27
- -
-38.33
-585.65
-348.9
-117.47
-49.15
15.55
5.97
8.64
7.08
19.65
-4.05
0.19
-7.45
-22.89
-20.34
Operating Margin (%)
- -
- -
2
2
2
1
- -
- -
- -
6
8
9
4
5
4
5
5
Depreciation Expense
- -
- -
-1
-8
-37
-13
-2
2
4
11
14
114
-27
-17
-51
-31
-18
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
8.03
24.91
34.55
7.87
- -
- -
- -
- -
- -
Effective Tax Rate (%)
1.08
- -
-28.1
-1,736.91
-3,824.4
-573.03
-49.18
17.95
5.03
4.59
2.52
17.43
-5.89
-4.67
-22.47
-21.95
-13.61
Profit Margin (%)
-13
13
14
9
3
-1
-2
21
25
13
52
271
151
129
181
155
- -
Working Capital
6
- -
1
1
- -
- -
- -
- -
- -
15
77
67
- -
- -
- -
- -
- -
LT Debt
17
80
79
71
34
21
19
21
25
126
137
242
232
219
229
207
- -
Total Equity
0.22
- -
- -
- -
- -
- -
- -
3.24
16.79
11.02
6.58
33.28
- -
- -
- -
- -
- -
Return on Invested Capital (%)
0.22
- -
- -
- -
- -
- -
- -
8.61
16.28
12.37
7.96
36.62
- -
- -
- -
- -
- -
Return on Capital (%)
0.33
- -
-1.77
-10.68
-70.28
-46.28
-9.09
8.99
17.45
14.59
10.69
60.15
-11.32
-7.44
-22.72
-14.17
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
5
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
106
51
68

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
191
- -
Cash, Cash Equivalents & STI
- -
24
- -
Accounts Receivable, Net
- -
26
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
37
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
5
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
48.78%
12.35%
-9.58%
Free Cash Flow
-739.45%
-76.19%
-72.77%
Net Income, GAAP
75.12%
142.89%
-39.29%
Sales/Revenue/Turnover
115.26%
-21.75%
-37.85%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
74
59
58
35
226
2026
29
43
32
36
141
2027
24
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.94
-1.31
-0.59
-4.07
-5.03
2026
-3.39
0.02
-0.53
0.85
-3.05
2027
-2.16
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Decipher Labs Ltd. (DECIPHER.BO) manufactures, markets, sells and trades pharmaceutical drugs in India and internationally through its Pharma and Consultancy segments; it offers branded and finished formulations including tablets, capsules and liquid orals such as anti-bacterial, antibiotic, anti-inflammatory, haematinic drugs and protein tonics, alongside bulk drugs and chemicals; it also provides information technology consultancy services encompassing technology integration and systems consulting, software development consulting, IT project management, ERP implementation, mobile and cloud solutions, product development and offshore services to formulators, manufacturers and research agencies. The company, founded in 1986 and headquartered at A-2, Q2, 5th Floor, Cyber Towers, Hitech City, Madhapur, Hyderabad, Telangana 500081, India, formerly operated as Combat Drugs Ltd. before changing its name to Decipher Labs Ltd. in January 2020; it expanded its IT presence by acquiring Decipher Software Solutions LLC in the USA to enhance turnover through specialized services, revived its information technology wing to strengthen associated technologies and continues custom manufacturing alongside branded products accepted across India with explorations into exports to regions like Nigeria and the West Indies.